⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51563 | 0.84 | EPHX2 (0.30) | — | |
| SCHEMBL25240125 | 0.82 | BCHE (0.33) | — | |
| SCHEMBL3763074 | 0.82 | NPC1 (0.36) | — | |
| SCHEMBL211520 | 0.78 | — | — | |
| SCHEMBL1131981 | 0.78 | — | — | |
| SCHEMBL25180839 | 0.77 | CYP2C9 (0.35) | — | |
| SCHEMBL28903229 | 0.77 | NOS3 (0.38) | — | |
| SCHEMBL21815374 | 0.77 | NOS3 (0.38) | — | |
| SCHEMBL211519 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL11895625 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932647-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | ABM THERAPEUTICS CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3684772-B1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM THERAPEUTICS CORP (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11254680-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | ABM THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
| US-11225485-B2 | — | — | 2022-01-18 | — | — | US | disclosed |
| US-20200247813-A1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM THERAPEUTICS CORPORATION (US) | 2020-08-06 | — | — | US | disclosed |
| EP-3684772-A1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM Therapeutics Corporation (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019060611-A1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM THERAPEUTICS, INC. (KY) | 2019-03-28 | — | — | WO | disclosed |
| US-9328120-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-03 | — | — | US | disclosed |
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2280981-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| US-7737166-B2 | Antifungal bicyclic hetero ring compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20090143353-A1 | such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1932837-A1 | BICYCLO HETEROCYCLIC COMPOUND HAVING ANTIFUNGAL ACTION | Daiichi Sankyo Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |